PCVX
Vaxcyte, Inc. NASDAQ Listed Jun 12, 2020$51.46
Mkt Cap $7.4B
52w Low $28.64
62.8% of range
52w High $65.00
50d MA $58.52
200d MA $46.49
P/E (TTM)
-10.1x
EV/EBITDA
-8.5x
P/B
2.9x
Debt/Equity
0.1x
ROE
-28.5%
P/FCF
-9.4x
RSI (14)
—
ATR (14)
—
Beta
1.39
50d MA
$58.52
200d MA
$46.49
Avg Volume
1.4M
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
825 Industrial Road · San Carlos, CA 94070 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -1.74 | -2.30 | -32.1% | 57.10 | -3.7% | -9.8% | — | — | — | — | — |
| Feb 24, 2026 | AMC | -1.53 | -1.80 | -17.7% | 61.35 | -5.8% | +2.8% | -4.8% | +2.9% | +0.4% | -3.5% | — |
| Nov 4, 2025 | AMC | -1.27 | -1.56 | -22.8% | 41.35 | -1.0% | -2.5% | +3.4% | -0.1% | +3.0% | +6.4% | — |
| Aug 6, 2025 | AMC | -1.12 | -1.22 | -8.9% | 33.00 | -8.9% | -9.1% | -0.4% | -0.8% | +1.1% | +5.2% | — |
| May 7, 2025 | AMC | -1.02 | -1.04 | -2.0% | 29.00 | +4.5% | +8.4% | -0.9% | +1.4% | -4.9% | -2.1% | — |
| Feb 25, 2025 | AMC | -1.16 | -1.02 | +12.1% | 79.35 | +4.5% | -0.9% | -5.6% | -1.6% | -1.3% | -2.6% | — |
| Nov 5, 2024 | AMC | -1.10 | -0.83 | +24.5% | 107.56 | +6.5% | -3.2% | -1.3% | +3.9% | -2.8% | -4.1% | — |
| Aug 6, 2024 | AMC | -0.98 | -1.10 | -12.8% | 73.93 | -0.2% | -4.6% | +4.4% | +5.8% | +0.3% | -1.1% | — |
| May 8, 2024 | AMC | -1.13 | -0.85 | +24.8% | 66.79 | -2.7% | -1.8% | -0.6% | +0.8% | +2.5% | +6.4% | — |
| Feb 27, 2024 | AMC | -0.90 | -1.82 | -102.2% | 81.05 | -3.0% | -7.3% | -1.7% | -2.9% | -0.2% | -0.1% | — |
| Nov 6, 2023 | AMC | -0.79 | -0.91 | -15.2% | 48.25 | -0.5% | +4.1% | +0.7% | -5.1% | +0.2% | +0.6% | — |
| Aug 8, 2023 | AMC | -0.67 | -0.70 | -4.5% | 48.87 | -1.8% | -3.9% | +1.1% | -0.5% | -2.6% | +3.2% | — |
| May 8, 2023 | AMC | -0.80 | -0.70 | +12.5% | 50.89 | +2.9% | +4.8% | -1.8% | -4.4% | -1.1% | +1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $63.04 | $61.67 | -2.2% | -4.8% | +2.9% | +0.4% | -3.5% | +0.5% |
| Feb 2 | Guggenheim | Maintains | Buy → Buy | — | $53.57 | $53.25 | -0.6% | +7.1% | -2.9% | -0.8% | -2.5% | +4.2% |
| Nov 10 | BTIG | Maintains | Buy → Buy | — | $41.65 | $42.01 | +0.9% | +3.0% | +6.4% | +1.0% | -1.2% | +6.9% |
| Oct 16 | BTIG | Maintains | Buy → Buy | — | $43.94 | $43.86 | -0.2% | -0.8% | -2.8% | +1.2% | -1.3% | +0.4% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $32.51 | $33.05 | +1.7% | -7.1% | +2.0% | -9.0% | +11.3% | +2.7% |
| Apr 1 | BofA Securities | Maintains | Buy → Buy | — | $37.76 | $37.12 | -1.7% | -14.6% | +4.5% | -9.3% | +3.4% | +2.9% |
| Apr 1 | Needham | Maintains | Buy → Buy | — | $37.76 | $37.12 | -1.7% | -14.6% | +4.5% | -9.3% | +3.4% | +2.9% |
| Apr 1 | Goldman Sachs | Maintains | Buy → Buy | — | $37.76 | $37.12 | -1.7% | -14.6% | +4.5% | -9.3% | +3.4% | +2.9% |
| Mar 12 | Guggenheim | Maintains | Buy → Buy | — | $69.85 | $70.00 | +0.2% | +4.9% | -0.3% | +1.8% | +1.2% | -0.7% |
| Feb 26 | Guggenheim | Maintains | Buy → Buy | — | $79.35 | $82.92 | +4.5% | -0.9% | -5.6% | -1.6% | -1.3% | -2.6% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $79.35 | $82.92 | +4.5% | -0.9% | -5.6% | -1.6% | -1.3% | -2.6% |
| Feb 24 | BTIG | Maintains | Buy → Buy | — | $79.74 | $79.78 | +0.1% | +2.4% | -2.9% | -0.9% | -5.6% | -1.6% |
| Feb 11 | Needham | Maintains | Buy → Buy | — | $85.94 | $84.53 | -1.6% | -0.9% | +0.3% | -1.8% | +0.2% | -1.8% |
| Dec 24 | BTIG | Maintains | Buy → Buy | — | $87.08 | $87.05 | -0.0% | -1.3% | -0.2% | -5.6% | +1.3% | -0.2% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $107.56 | $114.58 | +6.5% | -3.2% | -1.3% | +3.9% | -2.8% | -4.1% |
| Sep 10 | Mizuho | Maintains | Outperform → Outperform | — | $115.28 | $116.50 | +1.1% | +0.8% | -2.3% | +0.5% | +1.6% | -1.5% |
| Sep 4 | BofA Securities | Maintains | Buy → Buy | — | $110.15 | $113.05 | +2.6% | -0.9% | +2.7% | -0.5% | +3.3% | +0.8% |
| Sep 3 | Needham | Maintains | Buy → Buy | — | $80.76 | $107.67 | +33.3% | +36.4% | -0.9% | +2.7% | -0.5% | +3.3% |
| Sep 3 | BTIG | Maintains | Buy → Buy | — | $80.76 | $107.67 | +33.3% | +36.4% | -0.9% | +2.7% | -0.5% | +3.3% |
| Sep 3 | Jefferies | Maintains | Buy → Buy | — | $80.76 | $107.67 | +33.3% | +36.4% | -0.9% | +2.7% | -0.5% | +3.3% |
| Sep 3 | Leerink Partners | Maintains | Outperform → Outperform | — | $80.76 | $107.67 | +33.3% | +36.4% | -0.9% | +2.7% | -0.5% | +3.3% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $73.93 | $73.78 | -0.2% | -4.6% | +4.4% | +5.8% | +0.3% | -1.1% |
| Aug 7 | BTIG | Maintains | Buy → Buy | — | $73.93 | $73.78 | -0.2% | -4.6% | +4.4% | +5.8% | +0.3% | -1.1% |
| Jun 28 | Needham | Maintains | Buy → Buy | — | $78.77 | $78.83 | +0.1% | -4.1% | +1.9% | -1.1% | +0.3% | +2.0% |
| May 9 | Needham | Maintains | Buy → Buy | — | $66.79 | $65.00 | -2.7% | -1.8% | -0.6% | +0.8% | +2.5% | +6.4% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $64.51 | $62.74 | -2.7% | -3.1% | +3.7% | -4.6% | +0.8% | -0.2% |
| Mar 12 | Mizuho | Maintains | Buy → Buy | — | $70.25 | $71.52 | +1.8% | +2.0% | +2.3% | -5.4% | +0.6% | -2.4% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $81.05 | $78.65 | -3.0% | -7.3% | -1.7% | -2.9% | -0.2% | -0.1% |
| Jan 2 | BofA Securities | Maintains | Buy → Buy | — | $62.80 | $62.01 | -1.3% | +0.2% | -0.7% | +3.0% | -7.1% | +1.5% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $48.25 | $48.00 | -0.5% | +4.1% | +0.7% | -5.1% | +0.2% | +0.6% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $49.71 | $49.61 | -0.2% | -0.6% | +1.2% | -1.3% | +1.9% | +2.1% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $48.87 | $48.00 | -1.8% | -3.9% | +1.1% | -0.5% | -2.6% | +3.2% |
| May 9 | Needham | Maintains | Buy → Buy | — | $50.89 | $52.39 | +2.9% | +4.8% | -1.8% | -4.4% | -1.1% | +1.8% |
| Apr 18 | BofA Securities | Maintains | Buy → Buy | — | $42.34 | $43.52 | +2.8% | +4.2% | +3.8% | -0.9% | -0.6% | -3.9% |
| Apr 18 | TD Cowen | Maintains | Outperform → Outperform | — | $42.34 | $43.52 | +2.8% | +4.2% | +3.8% | -0.9% | -0.6% | -3.9% |
| Mar 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $40.97 | $41.24 | +0.7% | +1.7% | -0.4% | +2.5% | -3.1% | -0.9% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $42.30 | $40.00 | -5.4% | -3.1% | +1.7% | -0.4% | +2.5% | -3.1% |
| Feb 28 | Guggenheim | Maintains | Buy → Buy | — | $42.30 | $40.00 | -5.4% | -3.1% | +1.7% | -0.4% | +2.5% | -3.1% |
| Jan 3 | Needham | Maintains | Buy → Buy | — | $47.95 | $48.82 | +1.8% | -1.6% | -0.7% | -1.7% | +1.3% | -1.6% |
| Dec 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $45.48 | $45.36 | -0.3% | +0.7% | -6.4% | +4.8% | +3.4% | +2.5% |
| Dec 15 | Guggenheim | Maintains | Buy → Buy | — | $45.72 | $46.12 | +0.9% | -0.5% | +0.7% | -6.4% | +4.8% | +3.4% |
| Nov 17 | BTIG | Maintains | Buy → Buy | — | $43.35 | $43.33 | -0.0% | -0.2% | +1.8% | +1.4% | -1.1% | +0.0% |
| Nov 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $43.35 | $43.87 | +1.2% | +3.3% | -3.3% | +3.3% | -0.8% | -0.9% |
| Jul 7 | Needham | Maintains | Buy → Buy | — | $29.38 | $28.88 | -1.7% | -2.1% | +3.3% | -1.3% | +0.8% | -1.3% |
| Jul 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $29.38 | $28.88 | -1.7% | -2.1% | +3.3% | -1.3% | +0.8% | -1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Wassil JimOff | CHIEF OPERATING OFFICER | Sell | 2,250 | $56.83 | $128K | 160,744 | +2.74% | +2.97% |
8-K · 2.02
!! High
Vaxcyte, Inc. -- 8-K 2.02: Earnings Results
Vaxcyte reported Q1 2026 financial results, which investors should review for updates on vaccine development progress, cash burn rate, and runway before potential pivotal trial milestones.
May 6
8-K
Vaxcyte, Inc. -- 8-K Filing
Vaxcyte secured manufacturing capacity through Lonza's completed facility and North Carolina fill-finish expansion, positioning the company to commercialize pneumococcal vaccines with $2.4 billion in cash plus $600.2 million from a February 2026 equity offering.
Feb 24
8-K
Vaxcyte, Inc. -- 8-K Filing
Vaxcyte (PCVX) launched an at-the-market offering through Nasdaq with a placement agent receiving up to 3.0% compensation, allowing the company flexible capital raising at current market prices.
Feb 24
8-K
Vaxcyte, Inc. -- 8-K Filing
Vaxcyte completed an underwritten public offering, establishing customary legal protections and indemnification obligations between the company and underwriters for the securities transaction.
Feb 2
Data updated apr 26, 2026 7:01pm
· Source: massive.com